-
2022-10-28
专访优锐医药：呼吸精品特药领域，如何打造现金“造血”教科书？
近日，动脉新医药访谈了优锐医药创始人兼CEO Mark Lotter先生。Mark Lotter曾是阿斯利康的首批来华高管，拥有超过20年的中国医疗行业市场经验。Mark Lotter与我们分享了优锐医药如何练就现金“造血”能力，并逐步成长为具有差异化的特药医疗公司。
-
2022-10-14
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces additional exacerbation* subgroup analyses from the Phase 3 ENHANCE-2 (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) trial in chronic obstructive pulmonary disease
-
2022-09-07
优锐医药助力2022第十一届中国罕见病高峰论坛成功举办
2022年9月2日，第十一届中国罕见病高峰论坛于上海隆重开幕。本届大会以“初心如一 一路同行”为主题，作为国内历史最久，规模最大，影响力最为深远的中国罕见病领域综合性论坛
-
2022-08-18
Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China
Nuance Pharma announces the CDE has approved its Investigational New Drug ("IND") application supporting its pivotal clinical trial of Ensifentrine for the maintenance treatment of chronic obstructive pulm
-
2022-08-09
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces its top-line Phase 3 ENHANCE-2 (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) trial results evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD
-
2022-07-26
优锐医药：酮咯酸（NTM-001）I期临床试验受试者已完成研究药物输注
优锐医药今日宣布与Neumentum联合开发的非阿片类镇痛药物新型静脉输注酮咯酸（NTM-001）在香港大学一期临床试验中心实施的I期临床试验已完成所有志愿者药物输注。
-
2022-07-13
优锐医药携手蔻德罕见病中心，助力中国罕见病领域研究发展
2022年7月11日，优锐医药创始人Mark Lotter先生一行参访蔻德罕见病中心，与中心创始人黄如方先生及核心团队成员会面交谈，商讨加强研发合作机会，借力优锐医药链接、引进海内外优质医疗资源的经验优势，与蔻德罕见病中心广泛的社会影响力，共同推动中国罕见病领域的研究发展进程。
-
2022-06-27
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs
Contact PR
